ABIVAX Société Anonyme (FRA:2X1)

Market Cap	7.06B +1,697.4%
Revenue (ttm)	4.57M -63.2%
Net Income	-336.10M
EPS	-4.83
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30
Average Volume	61
Open	94.30
Previous Close	95.70
Day's Range	87.40 - 94.30
52-Week Range	4.58 - 129.20
Beta	n/a
RSI	36.50
Earnings Date	Mar 23, 2026

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 67
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2X1

Financial Performance

In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.